Glycobiology Market Size is estimated to grow at a substantial rate from 2022 and 2028. The field constitutes the study of the biology, function, and structure of carbohydrates, also called glycans. These are complex and diverse molecules and their unique structures help in the determination of their functions.
In view of the central role played by glycans in immune interactions, carbohydrates and glycoproteins are becoming the targets of next-generation diagnostics, therapeutics, and vaccines. In addition, glycan molecules are used for modulating numerous processes including metabolic and gene regulation, cell and tissue differentiation, protein clearance, protein activity, and others.
On the basis of product, the enzyme segment is expected to contribute a lucrative share to the market through 2028. This is mainly on account of the crucial role of enzymes in the field of glycobiology. Citing an instance, transferases are involved in the synthesis of complex carbohydrates, that are metabolized by glycosidases and modified through various enzymes such as sulfatases. As a result, the enzymes may be used as useful tools for understanding the carbohydrate structure and function. They might also be utilized for the delineation or determination of the structure of an oligosaccharide of interest or for the modulation of carbohydrate structure for seeing how it affects its biological functions.
Based on end-use, the glycobiology market is projected to record considerable growth from drug discovery and development application over the coming years. This rise is predominantly attributed to the increasing usage of glycobiology in the production of numerous drugs that have enhanced human health. The field is gaining increasing prominence due to rising advancements in the field of glycoproteomics, genomics, and tools from chemical biology. Furthermore, dysregulated glycosylation plays a vital part in disease processes from immune evasion to cognition, leading to research activities that target glycans for therapeutic benefit.
North America glycobiology market is poised to register substantial growth through 2028 owing to an increase in research activities in the region. For instance, the intramural NIH (National Institute of Health) undertakes various cross-cutting research activities for making it an ideal environment for studies in the field of glycosciences. Additionally, the Glycobiology Scientific Interest Group constitutes a core group of laboratories that represent numerous institutes and the U.S. Food and Drug Administration.
Major players in the industry include ProZyme (Agilent Technologies, Inc.), Danaher, Thermo Fisher Scientific, Inc., WATERS, Bruker, New England Biolabs, Agilent Technologies, Inc. These glycobiology companies are focused on the implementation of strategic initiatives such as acquisitions, mergers, product developments, partnerships, and collaborations for maintaining their position in the industry.
For instance, in May 2021, New England Biolabs, Inc., inked a partnership agreement for the acquisition of Fluorogenics Limited (FGL), a UK-based R&D service firm. Under the agreement, FGL is set to become NEB’s wholly-owned subsidiary.
The COVID-19 crisis has witnessed the increasing contribution of glycobiology for numerous candidate drugs including recombinant lectins, glycans for vaccines, lectin inhibitors, anti-glycan antibodies, polysaccharides, glycosidase inhibitors, and numerous glycosides. This indicates a greater emphasis on some opportunities for repurposing FDA-approved drugs. Studies estimate that the next-generation of SARS-CoV-2 drugs could be based on the essential glycobiological insight on glycosidases, glycosyltransferases, glycan-binding proteins, and glycans.
Market, by Product
Market, by Application
Market, by End-use
The above information is provided for the following regions and countries: